The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment in the total insulin market was long-acting insulin. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin, premixed insulin and human insulin segments.
Combined with steady appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total insulin market over the forecast period. In terms of volume market share, premixed insulin represents the smallest portion of the total insulin market as well. It is expected that this trend will continue and ASP appreciation will follow the general upward trend of the total insulin market over the forecast period.
Key Topics Covered:
Table Of Contents I
List Of Figures Iv
List Of Charts Vi
U.S. Diabetes Monitoring, Treatment And Drug Delivery Market Overview
Procedure Codes Investigated
Key Report Updates
Johnson & Johnson
For more information about this report visit http://www.researchandmarkets.com/research/86d5cx/us_market_report